NCT00118963View on ClinicalTrials.gov

Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Metformin

Tablets of 500 mg; 1000 mg two times daily.

DRUG

Insulin BIAsp30 (Novolog 70/30)

Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.

DRUG

Repaglinide

Tablets of 1 mg; Dosage: 2 mg three times daily.

DRUG

Placebo-Metformin

Tablets corresponding to 500 mg; two tablets two times daily.

DRUG

Placebo-Repaglinide

Tablet corresponding to 1 mg; two tablets three times daily.

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

All Listed Sponsors
lead

Steno Diabetes Center Copenhagen

OTHER

NCT00118963 - Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes | Biotech Hunter | Biotech Hunter